Media

ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression b

MYR Pharmaceuticals today announced that the final results of the MYR203 study of bulevirtide (Myrcludex), MYR´s first-in-class entry inhibitor for treatment of hepatitis B and D infection, will be presented at the General Session of the upcoming 2019 ILC meeting in Vienna

MYR Pharmaceuticals announced today that the British Medicines and Healthcare products Regulatory Agency (MHRA) has issued the Promising Innovative Medicine (PIM) designation for MYR’s lead compound Bulevirtide (Myrcludex). The designation is granted in the indication of chronic hepatitis delta virus (HDV) infection.

BAD HOMBURG, Germany, October 29, 2018 / PRNewswire / -- MYR Pharma today announced that the results of 48 weeks of administration of Myrcludex, MYR`s first-in-class entry inhibitor for treatment of hepatitis B and D infection, will be presented at the Presidential Plenary Session of the upcoming meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco: